Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma (Q78842136)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548597%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

title

Phase II trial of cyclophosphamide, vincristine, and dexamethasone in the treatment of androgen-independent prostate carcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548597%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

1 reference

phase II clinical trial

1 reference

1 reference

Danai D Daliani

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548597%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

Vasily Assikis

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548597%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

Shi-Ming Tu

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548597%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

Christos N Papandreou

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548597%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

Lance C Pagliaro

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548597%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

Tammy Holtkamp

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548597%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

Xumei Wang

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548597%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

Peter F Thall

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548597%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

Christopher J Logothetis

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548597%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

publication date

1 February 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548597%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

number of pages

7

1 reference

inferred from page(s)

published in

Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548597%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

volume

97

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548597%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548597%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

page(s)

561-567

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548597%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

cites work

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11078

7 January 2021

Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11078

7 January 2021

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11078

7 January 2021

Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11078

7 January 2021

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11078

7 January 2021

Serum prostate-specific antigen decline as a marker of clinical outcome in hormone-refractory prostate cancer patients: association with progression-free survival, pain end points, and survival

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11078

7 January 2021

Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11078

7 January 2021

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11078

7 January 2021

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11078

7 January 2021

Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11078

7 January 2021

Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11078

7 January 2021

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11078

7 January 2021

Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11078

7 January 2021

Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11078

7 January 2021

Oral cyclophosphamide for the management of hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11078

7 January 2021

Phase III trial of cyclophosphamide versus cyclophosphamide, doxorubicin, and methotrexate in hormone-refractory prostatic cancer. A Hoosier Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11078

7 January 2021

Adriamycin and cyclophosphamide versus hydroxyurea in advanced prostatic cancer. A randomized Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11078

7 January 2021

Oral estramustine and cyclophosphamide in patients with metastatic hormone refractory prostate carcinoma: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11078

7 January 2021

Phase II study of the oral cyclophosphamide and oral etoposide combination in hormone-refractory prostate carcinoma patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11078

7 January 2021

Comparison of Estramustine Phosphate and Vincristine Alone or in Combination for Patients with Advanced, Hormone Refractory, Previously Irradiated Carcinoma of the Prostate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11078

7 January 2021

Treatment of androgen-independent prostate cancer with dexamethasone: a prospective study in stage D2 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11078

7 January 2021

Low doses of oral dexamethasone for hormone-refractory prostate carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11078

7 January 2021

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11078

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11078

7 January 2021

Identifiers

DOI

10.1002/CNCR.11078

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12548597%20AND%20SRC:MED&resulttype=core&format=json

17 December 2019

1 reference